Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

Zhichen Sun,Yanhong Chu,Jie Xiao,Yueling Yang,Fanyan Meng,Xinyue Wang,Yanbing Dong,Junmeng Zhu,Yirong Wu,Lanqun Qin,Yaohua Ke,Baorui Liu,Qin Liu
DOI: https://doi.org/10.1186/s12967-023-04504-w
IF: 8.44
2023-09-14
Journal of Translational Medicine
Abstract:In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical and clinical studies. However, the design of in situ tumor vaccines still needs further optimization and the underlying immune mechanism also waits for deeper investigation.
medicine, research & experimental
What problem does this paper attempt to address?